Format

Send to

Choose Destination
Radiol Bras. 2017 Sep-Oct;50(5):299-307. doi: 10.1590/0100-3984.2016.0117.

Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer.

Author information

1
MD, Department of Urology, University of California San Francisco, San Francisco, CA, USA.
2
MD, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
3
PhD, Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
4
MPH, MD, Department of Urology, University of California San Francisco, San Francisco, CA, USA.
5
MD, PhD, Department of Radiology and Biomedical Imaging and Department of Urology, University of California San Francisco, San Francisco, CA, USA.

Abstract

in English, Portuguese

OBJECTIVE:

To compare the predictions of dominant Gleason pattern ≥ 4 or non-organ confined disease with Prostate Imaging Reporting and Data System (PI-RADS v2) with or without proton magnetic resonance spectroscopic imaging (1H-MRSI).

MATERIALS AND METHODS:

Thirty-nine men underwent 3-tesla endorectal multiparametric MRI including 1H-MRSI and prostatectomy. Two radiologists assigned PI-RADS v2 and 1H-MRSI scores to index lesions. Statistical analyses used logistic regressions, receiver operating characteristic (ROC) curves, and 2x2 tables for diagnostic accuracies.

RESULTS:

The sensitivity and specificity of 1H-MRSI and PI-RADS v2 for high-grade prostate cancer (PCa) were 85.7% (57.1%) and 92.9% (100%), and 56% (68.0%) and 24.0% (24.0%). The sensitivity and specificity of 1H-MRSI and PI-RADS v2 for extra-prostatic extension (EPE) were 64.0% (40%) and 20.0% (48%), and 50.0% (57.1%) and 71.4% (64.3%). The area under the ROC curves (AUC) for prediction of high-grade prostate cancer were 0.65 and 0.61 for PI-RADS v2 and 0.72 and 0.70 when combined with 1H-MRSI (readers 1 and 2, p = 0.04 and 0.21). For prediction of EPE the AUC were 0.54 and 0.60 for PI-RADS v2 and 0.55 and 0.61 when combined with 1H-MRSI (p > 0.05).

CONCLUSION:

1H-MRSI might improve the discrimination of high-grade prostate cancer when combined to PI-RADS v2, particularly for PI-RADS v2 score 4 lesions, but it does not affect the prediction of EPE.

KEYWORDS:

Diagnosis; MRI; Prostate cancer; Prostatectomy; Spectroscopy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center